AEMD Stock Price, Aethlon Medical Inc Quote, Chart

Market Summary

USD1.53+0.02

Delayed

1.32%

AEMD Stock Price

View Fullscreen

AEMD RSI Chart

AEMD Valuation

Market Cap

4.0M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

1.07

Price/Free Cashflow

-0.37

AEMD Price/Sales (Trailing)

AEMD Profitability

Return on Equity

-160.94%

Return on Assets

-117.37%

Free Cashflow Yield

-268.59%

AEMD Fundamentals

AEMD Revenue

Revenue (TTM)

3.7M

Rev. Growth (Yr)

-8.37%

Rev. Growth (Qtr)

-41%

AEMD Earnings

Earnings (TTM)

-12.2M

Earnings Growth (Yr)

-21.63%

Earnings Growth (Qtr)

-14.23%

Breaking Down AEMD Revenue

Last 7 days

7.8%

Last 30 days

-12.1%

Last 90 days

-20.3%

Trailing 12 Months

240%

How does AEMD drawdown profile look like?

AEMD Financial Health

Current Ratio

3.93

AEMD Investor Care

Shares Dilution (1Y)

14.08%

Diluted EPS (TTM)

-4.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.5M	3.7M	3.8M	3.7M
2022	2.6M	2.9M	3.2M	3.5M
2021	2.6M	2.7M	2.6M	2.5M
2020	2.7M	2.7M	2.6M	2.6M
2019	2.2M	2.3M	2.7M	2.7M
2018	1.9M	2.0M	2.0M	2.6M
2017	2.2M	1.9M	1.8M	1.5M
2016	2.3M	2.3M	2.4M	2.4M
2015	1.6M	1.7M	1.8M	2.1M
2014	1.6M	1.7M	1.7M	1.2M
2013	1.9M	1.7M	1.6M	1.7M
2012	1.6M	1.7M	1.9M	1.9M
2011	1.1M	1.3M	1.2M	1.3M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aethlon Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	rossetti angela	acquired	49,998	1.52	32,894	-
Apr 16, 2024	broenniman edward g	acquired	49,998	1.52	32,894	-
Apr 16, 2024	gikakis nicolas	acquired	49,998	1.52	32,894	-
Apr 16, 2024	shah chetan	acquired	49,998	1.52	32,894	-
Mar 29, 2024	shah chetan	sold (taxes)	-1,953	1.68	-1,163	-
Mar 29, 2024	broenniman edward g	sold (taxes)	-1,953	1.68	-1,163	-
Mar 29, 2024	gikakis nicolas	sold (taxes)	-3,282	1.68	-1,954	-
Dec 29, 2023	broenniman edward g	sold (taxes)	-2,546	2.19	-1,163	-
Dec 29, 2023	shah chetan	sold (taxes)	-2,546	2.19	-1,163	-
Dec 29, 2023	gikakis nicolas	sold (taxes)	-4,279	2.19	-1,954	-

Which funds bought or sold AEMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-151	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-43,050	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	46,481	46,481	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-5,372	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-9,743	-	-%
Feb 14, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	new	-	57.00	57.00	-%
Feb 14, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	sold off	-100	-60.00	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	new	-	2,886	2,886	-%

Are Funds Buying or Selling AEMD?

Are funds buying AEMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AEMD

No. of Funds

Unveiling Aethlon Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 13, 2022	empery asset management, lp	0.68%	105,000	SC 13G/A
Jun 15, 2021	empery asset management, lp	9.82%	1,388,079	SC 13G
Feb 22, 2021	iroquois capital management, llc	0.86%	104,572	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	1.5%	179,116	SC 13G/A
Jan 13, 2021	empery asset management, lp	4.99%	825,020	SC 13G
Feb 14, 2020	iroquois capital management, llc	6.3%	110,701	SC 13G/A
Feb 11, 2020	intracoastal capital, llc	9.99%	324,082	SC 13G/A
Jan 27, 2020	empery asset management, lp	4.99%	30,545	SC 13G/A
Jan 27, 2020	empery asset management, lp	7.73%	506,700	SC 13G
Jan 24, 2020	armistice capital, llc	3.8%	315,648	SC 13G

Recent SEC filings of Aethlon Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 05, 2024	S-1/A	Initial Public Offering
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 22, 2024	S-1	Initial Public Offering
Feb 14, 2024	8-K	Current Report

Peers (Alternatives to Aethlon Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

Aethlon Medical Inc News

Latest updates

Aethlon Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-41.0%	669	1,133	977	971	730	1,004	844	968	433	649	583	792	625	656	564	749	610	762	608	748	587
Operating Expenses	12.3%	3,567	3,175	3,408	3,052	2,850	3,665	2,906	3,799	2,545	2,141	2,230	2,299	3,069	1,771	1,410	1,992	1,290	1,702	1,596	1,671	1,964
S&GA Expenses	15.1%	979	851	1,308	828	1,071	1,548	1,032	1,027	1,112	686	630	573	921	555	409	550	274	342	383	272	215
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.00	72.00	-	-
Net Income	-14.2%	-3,466	-3,034	-3,282	-2,466	-2,849	-3,807	-2,906	-3,784	-2,525	-2,008	-2,098	-2,259	-2,444	-1,771	-1,411	-1,781	-819	-1,706	-2,067	-1,634	-2,013
Net Income Margin	-7.0%	-3.27*	-3.05*	-3.37*	-3.39*	-3.76*	-4.01*	-3.88*	-3.95*	-3.62*	-3.33*	-3.23*	-2.99*	-2.86*	-2.24*	-	-	-	-	-	-	-
Free Cashflow	12.0%	-2,386	-2,710	-2,712	-2,958	-2,102	-3,617	-2,770	-3,311	-2,776	-1,918	-2,110	-2,243	-2,228	-1,232	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.6%	10,437	12,828	15,801	17,509	20,724	23,047	17,132	19,418	21,916	23,874	25,867	10,669	12,670	15,056	16,427	10,388	4,682	1,282	2,933	4,123	4,951
Current Assets	-21.3%	8,249	10,487	13,308	15,091	18,172	20,504	15,894	18,157	21,210	23,569	25,548	10,352	12,322	14,752	16,095	10,041	4,306	900	2,644	4,038	4,860
Cash Equivalents	-21.7%	7,972	10,176	12,898	14,620	17,500	19,604	14,922	17,160	20,395	23,225	25,172	9,908	12,178	14,473	15,722	9,605	4,059	786	2,492	3,828	4,825
Net PPE	-7.2%	1,114	1,200	1,284	1,144	1,212	1,139	452	441	254	214	188	161	167	146	150	140	145	125	6.00	6.00	10.00
Liabilities	12.6%	2,825	2,509	2,692	2,445	3,445	3,179	2,212	2,427	1,357	-	-	1,375	1,236	1,490	1,240	1,110	878	1,261	1,915	1,824	1,781
Current Liabilities	22.8%	2,101	1,711	1,822	1,505	2,436	2,101	1,645	1,824	1,070	974	1,131	1,375	1,236	1,490	1,223	1,068	811	1,169	1,797	1,824	1,781
Shareholder's Equity	-26.2%	7,611	10,319	13,109	15,064	17,279	19,868	14,920	16,991	20,559	22,900	24,736	9,294	11,434	13,567	15,187	9,277	3,804	21.00	1,018	2,299	3,170
Retained Earnings	-2.3%	-152,141	-148,675	-145,640	-142,358	-139,892	-137,042	-133,234	-130,329	-126,544	-124,018	-122,010	-119,913	-117,650	-115,207	-113,436	-112,026	-110,243	-109,423	-107,718	-105,652	-104,010
Additional Paid-In Capital	0.5%	159,752	159,002	158,732	157,427	157,148	156,888	148,281	147,447	147,229	147,042	146,869	129,332	129,207	128,896	128,745	121,427	114,173	109,572	108,845	108,076	107,284
Shares Outstanding	4.2%	2,597	2,493	2,484	2,299	2,295	2,075	1,549	1,542	1,454	1,411	1,283	1,542	1,209	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-142	-141	-141	-138	-138	-136	-135	-133	-132	-132	-129	-128	-126	-126	-122
Float	-	-	-	-	-	-	13,200	-	-	-	58,900	-	-	-	16,200	-	-	-	4,500	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.1%	-2,377	-2,704	-2,482	-2,946	-1,951	-2,878	-2,728	-3,099	-2,718	-1,878	-2,071	-2,238	-2,197	-1,226	-1,101	-1,620	-1,256	-1,073	-1,247	-1,397	-1,086
Share Based Compensation	122.8%	573	257	250	260	263	314	215	228	201	201	120	150	378	167	84.00	88.00	103	327	327	374	345
Cashflow From Investing	-30.1%	-8.81	-6.77	-230	-11.29	-151	-739	-41.17	-212	-57.93	-40.49	-38.37	-5.25	-31.49	-5.33	-17.81	-3.60	-28.08	-119	-886*	-	-
Cashflow From Financing	1899.5%	177	-9.84	1,078	-2.64	-1.88	8,300	619	-10.64	-13.56	-28.13	17,420	-26.14	-66.01	-16.13	7,237	7,170	4,557	-514	-87.15	401	833

AEMD Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES
Professional fees	$ 668,586	$ 729,665	$ 2,778,335	$ 2,575,496
Payroll and related expenses	1,919,305	1,048,761	4,233,970	3,191,402
General and administrative	979,197	1,071,327	3,138,289	3,653,832
Total operating expenses	3,567,088	2,849,753	10,150,594	9,420,730
OPERATING LOSS	(3,567,088)	(2,849,753)	(10,150,594)	(9,420,730)
OTHER EXPENSE/(INCOME)
Loss on dissolution of subsidiary	0	0	0	142,121
Interest and Other Income	(100,967)	0	(367,838)	0
NET LOSS	(3,466,121)	(2,849,753)	(9,782,756)	(9,562,851)
OTHER COMPREHENSIVE INCOME	7,951	0	4,522	0
COMPREHENSIVE LOSS	$ (3,458,170)	$ (2,849,753)	$ (9,778,234)	$ (9,562,851)

AEMD Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current assets
Cash	$ 7,972,012	$ 14,532,943
Prepaid expenses and other current assets	277,321	557,623
Total current assets	8,249,333	15,090,566
Property and equipment, net	1,113,880	1,144,004
Right-of-use lease asset, net	951,466	1,151,909
Patents, net	1,238	1,650
Restricted cash	87,506	87,506
Deposits	33,305	33,305
Total assets	10,436,728	17,508,940
Current liabilities
Accounts payable	693,154	432,890
Due to related parties	656,045	214,221
Lease liability, current portion	285,095	269,386
Other current liabilities	466,329	588,592
Total current liabilities	2,100,623	1,505,089
Lease liability, less current portion	724,848	939,642
Total liabilities	2,825,471	2,444,731
Stockholders’ Equity
Common stock, par value $0.001 per share; 60,000,000 shares authorized as of December 31, 2023 and March 31, 2023; 2,596,538 and 2,299,259 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively	2,596	2,299
Additional paid-in capital	159,751,591	157,426,606
Accumulated other comprehensive loss	(1,619)	(6,141)
Accumulated deficit	(152,141,311)	(142,358,555)
Total stockholders’ equity	7,611,257	15,064,209
Total liabilities and stockholders’ equity	$ 10,436,728	$ 17,508,940

About Aethlon Medical Inc

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

CEO	Dr. Charles J. Fisher Jr., M.D.
WEBSITE	aethlonmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	15

Aethlon Medical Inc Frequently Asked Questions

What is the ticker symbol for Aethlon Medical Inc? What does AEMD stand for in stocks?

AEMD is the stock ticker symbol of Aethlon Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aethlon Medical Inc (AEMD)?

As of Wed Apr 24 2024, market cap of Aethlon Medical Inc is 4.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers.

What is the fair value of AEMD stock?

You can check AEMD's fair value in chart for subscribers. The fair value of Aethlon Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aethlon Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AEMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aethlon Medical Inc a good stock to buy?

The fair value guage provides a quick view whether AEMD is over valued or under valued. Whether Aethlon Medical Inc is cheap or expensive depends on the assumptions which impact Aethlon Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AEMD.

What is Aethlon Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, AEMD's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 1.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AEMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aethlon Medical Inc's stock?

In the past 10 years, Aethlon Medical Inc has provided -0.374 (multiply by 100 for percentage) rate of return.